cardiology
Medicines

Cardiotoxicity risk from anthracyclines ‘lifelong’

More childhood cancer survivors are experiencing cardiomyopathy and other cardiotoxicities years after treatment with anthracyclines than previously thought, say researchers who have reported the first outcomes from an Australian cohort of paediatric cancer survivors. Cardiologists and oncologists are now calling on national bodies to fund a paediatric cancer survivor register and are urging doctors to ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic